Angiographic endpoints in progression trials

The use of different angiographic criteria represents one of the reasons why the results of angiographic trials are difficult to compare. In principle, this is an avoidable problem and therefore a serious attempt at standardization should be made. This chapter reviews the criteria which have been used in trials using quantitative coronary angiography and presents a proposal for standardization.

[1]  M-heart investigators Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) , 1994, The Lancet.

[2]  B. Rosner,et al.  Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients , 1994, The Lancet.

[3]  G J Boerma,et al.  Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). , 1995, Circulation.

[4]  James P. Martucci,et al.  Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. , 1994, Circulation.

[5]  M J Malloy,et al.  Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. , 1990, JAMA.

[6]  D. Waters,et al.  Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. , 1994, Circulation.

[7]  Stanley Azen,et al.  Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS) , 1993, Annals of Internal Medicine.

[8]  G. Schuler,et al.  Regular Physical Exercise and Low‐Fat Diet: Effects on Progression of Coronary Artery Disease , 1992, Circulation.

[9]  G. Watts,et al.  Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS) , 1992, The Lancet.

[10]  B Buis,et al.  Arteriographic evaluation of small coronary arteries. , 1990, Journal of the American College of Cardiology.

[11]  E. Alderman,et al.  Development of new coronary atherosclerotic lesions during a 4-year multifactor risk reduction program: the Stanford Coronary Risk Intervention Project (SCRIP). , 1994, Journal of the American College of Cardiology.

[12]  J. Reiber,et al.  Catheter sizes for quantitative coronary arteriography. , 1994, Catheterization and cardiovascular diagnosis.

[13]  J J Albers,et al.  Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. , 1990, The New England journal of medicine.

[14]  R. Krauss,et al.  Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). , 1994, Circulation.